Kenrick Ng speaks to ecancer about the emergence of PARP inhibitors in the prostate cancer setting.

Kenrick explains that the emergence of PARP inhibitors is part of a new era of precision medicine and biomarker selected treatment in prostate cancer.

He gives some advantages and disadvantages of this treatment option, including some practical considerations for clinicians and the challenges that come with the need for genomic profiling.

Kenrick concludes by saying that clinicians should expect a general push towards genomic testing and precision medicine, so it is important to keep up and update practices accordingly.

This programme has been supported by an unrestricted educational grant from Pfizer.